Get the Stockscreener App
50.42
2.06%
1.02
After Hours:
50.42
Moonlake Immunotherapeutics stock is traded at $50.42, with a volume of 288.05K.
It is up +2.06% in the last 24 hours and up +7.76% over the past month.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.
See More
Previous Close:
$49.40
Open:
$49.41
24h Volume:
288.05K
Relative Volume:
0.89
Market Cap:
$3.17B
Revenue:
-
Net Income/Loss:
$-54.80M
P/E Ratio:
-43.12
EPS:
-1.1692
Net Cash Flow:
$-64.65M
1W Performance:
-8.99%
1M Performance:
+7.76%
6M Performance:
+0.38%
1Y Performance:
-11.54%
1-Day Range:
$49.41
$52.74
1-Week Range:
$49.39
$55.58
52-Week Range:
$35.11
$64.98
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Name
Moonlake Immunotherapeutics
Sector
Industry
Phone
41 41 510 8022
Address
DORFSTRASSE 29, ZUG
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Nov-02-23 | Initiated | Stifel | Buy |
| Sep-14-23 | Downgrade | Bryan Garnier | Buy → Neutral |
| Aug-31-23 | Initiated | Needham | Buy |
| Jun-15-23 | Initiated | Barclays | Equal Weight |
| May-01-23 | Initiated | Guggenheim | Buy |
| Mar-22-23 | Initiated | Wedbush | Outperform |
| Mar-09-23 | Initiated | BTIG Research | Buy |
| Feb-14-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-02-23 | Initiated | Bryan Garnier | Buy |
| Nov-11-22 | Initiated | Jefferies | Buy |
| Aug-25-22 | Initiated | SVB Leerink | Outperform |
| Jul-21-22 | Initiated | H.C. Wainwright | Buy |
| Jul-07-22 | Initiated | Cowen | Outperform |
View All
Moonlake Immunotherapeutics Stock (MLTX) Latest News
MoonLake Immunotherapeutics' SWOT analysis: stock outlook amid clinical trials - Investing.com
Marshall Wace LLP Has $48.31 Million Stake in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Acquired by Marshall Wace LLP - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 5.8% - Defense World
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Sold by Fred Alger Management LLC - Defense World
MoonLake Immunotherapeutics (MLTX) – Research Analysts’ Recent Ratings Updates - Defense World
MoonLake Immunotherapeutics to Post FY2024 Earnings of ($1.37) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:MLTX) - Defense World
Brokers Issue Forecasts for MoonLake Immunotherapeutics' FY2024 Earnings (NASDAQ:MLTX) - MarketBeat
Is MoonLake Immunotherapeutics (MLTX) the Best Guru Stock To Buy Now? - Insider Monkey
Is MoonLake Immunotherapeutics (MLTX) the Best Guru Stock To Buy Now? - Yahoo Finance
Logos Global Management LP Takes Position in MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
750,000 Shares in MoonLake Immunotherapeutics (NASDAQ:MLTX) Purchased by Logos Global Management LP - MarketBeat
Integral Health Asset Management LLC Sells 200,000 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
10 Best Guru Stocks To Buy Now - Insider Monkey
Integral Health Asset Management LLC Has $9.67 Million Stake in MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
HighVista Strategies LLC Lowers Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
Westwood Holdings Group Inc. Has $8.63 Million Stock Position in Monolithic Power Systems, Inc. (NASDAQ:MPWR) - Defense World
MoonLake Immunotherapeutics’ (MLTX) Overweight Rating Reiterated at Cantor Fitzgerald - Defense World
Cantor Fitzgerald Reaffirms Overweight Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
Avoro Capital Advisors LLC Has $121.80 Million Stock Position in MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
MoonLake Immunotherapeutics (MLTX): Short Seller Sentiment is Bearish On This ADR Stock - Insider Monkey
MoonLake Immunotherapeutics (MLTX): Short Seller Sentiment is Bearish On This ADR Stock - Yahoo Finance
10 Worst ADR Stocks To Buy According to Short Sellers - Insider Monkey
MillerKnoll (NASDAQ:MLKN) Posts Quarterly Earnings Results - Defense World
MoonLake Immunotherapeutics (MLTX) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Up 5.6% - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Up 5.6% - Defense World
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 4% - MarketBeat
Victory Capital Management Inc. Purchases 24,037 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
Victory Capital Management Inc. Acquires 24,037 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
Federated Hermes Inc. Purchases 28,672 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Rating Reiterated by Needham & Company LLC - Defense World
MoonLake Immunotherapeutics (NASDAQ:MLTX) Rating Reiterated by HC Wainwright - Defense World
MLTX’s Stock Market Adventure: -15.48% YTD Growth Amidst Volatility - The InvestChronicle
H.C. Wainwright maintains Buy rating on Moonlake Immunotherapeutics stock - Investing.com
BTIG sees Moonlake stock as a buy, driven by sonelokimab’s market growth prospects - Investing.com India
H.C. Wainwright maintains Buy rating on Moonlake Immunotherapeutics stock By Investing.com - Investing.com Canada
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given "Buy" Rating at Needham & Company LLC - MarketBeat
Moonlake Immunotherapeutics retains Buy stock rating on HS, PsA potential - Investing.com India
Moonlake Immunotherapeutics retains Buy stock rating on HS, PsA potential - Investing.com
BTIG sees Moonlake stock as a buy, driven by sonelokimab’s market growth prospects - Investing.com
MoonLake Immunotherapeutics Capital Markets Day Preview - TipRanks
TD Asset Management Inc Acquires 5,140 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
Zurcher Kantonalbank Zurich Cantonalbank Reduces Position in MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
MoonLake Immunotherapeutics (NASDAQ:MLTX) Rating Reiterated by Cantor Fitzgerald - MarketBeat
MLTXMoonLake Immunotherapeutics Latest Stock News & Market Updates - StockTitan
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11 - GlobeNewswire
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11 - StockTitan
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11 - Informazione.it
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Moonlake Immunotherapeutics Stock (MLTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):